Internal Server Error

Octozi - About the company

Octozi is a seed company based in Russia, founded in 2023 by Amit Patel. It operates as an Accelerating life sciences with generative AI. Octozi has raised $3M in funding from Surface Ventures. The company has 1988 active competitors, including 102 funded and 207 that have exited. Its top competitors include companies like AbbVie, Gilead and Amgen.

Company Details

Accelerating life sciences with generative AI. It helps sponsors integrate disparate datasets, automate clinical development processes, and accelerate data cleaning and review. This automation, powered by Generative Artificial Intelligence (AI) and advanced machine learning analytics, significantly reduces time to market. The platform improves patient safety through AI-driven early safety signal detection, enabling faster corrective actions. It offers real-time detection of clinical data discrepancies, going beyond basic edit checks. The AI visualizes and monitors clinical data for safety and efficacy, identifying nuanced and critical risks. A core design principle is security, ensuring compliance and data privacy. Robust accreditation and certifications meet industry gold standards for information security, patient data privacy, and compliance. The platform is designed to handle the needs of various life science organizations across all phases of clinical trials and therapeutic areas. It uses custom-developed large language models (LLMs) for optimal performance. All data remains confidential and is never used to train models.
Key Metrics
Founded Year
2023
Location
Stage
Seed
Total Funding
$3M in 2 rounds
Latest Funding Round
Ranked
Employee Count
6 as on Aug 31, 2026
Similar Companies
Sign up to download Octozi's company profile

Octozi's funding and investors

Octozi has raised a total funding of $3M over 2 rounds. Its latest funding round was a Seed round on Jul 07, 2026 for $*****. 2 investors participated in its latest round. Octozi has 3 institutional investors.

Here is the list of recent funding rounds of Octozi:
Date of Funding
Funding Amount
Round Name
Post-Money Valuation
Revenue Multiple
Lead Investors
Other Investors
Jul 07, 2026
2603748
Seed
6926149
2323584
7453450
6489927
lockAccess funding benchmarks and valuations. Sign up today!

Octozi's founders and board of directors

Founder? Claim Profile
The founders of Octozi is Amit Patel.
Here are the details of Octozi's key team members:

Octozi's employee count trend

Octozi has 6 employees as of Aug 26. Here is Octozi's employee count trend over the years:
Employee count trend for Octozi
lockUncover Octozi's growth story! Sign up today!
chrome_extension_cta_illustration
Access Tracxn on any website
Our Google Chrome extension lets you view company details while browsing their websites
Install Tracxn Extension

Octozi's Competitors and alternates

Top competitors of Octozi include AbbVie, Gilead and Amgen. Here is the list of Top 10 competitors of Octozi, ranked by Tracxn score:
Rank
Company Details
Short Description
Total Funding
Investors
Tracxn Score
1st
Logo for AbbVie
AbbVie
2012, Chicago (United States), Public
Research-based biopharmaceutical company
$14.7B
83/100
2nd
Logo for Gilead
Gilead
1987, Foster City (United States), Acquired
Developer of medicines to treat HIV/AIDS, liver diseases, cancer & others
-
81/100
3rd
Logo for Amgen
Amgen
1980, Thousand Oaks (United States), Public
Developer of pharmaceutical products for treating multiple diseases
-
79/100
4th
Logo for AstraZeneca
AstraZeneca
1999, Cambridge (United Kingdom), Public
Developer of pharmaceutical medicines for oncology and various chronic diseases
-
76/100
5th
Logo for Lilly
Lilly
1876, Indianapolis (United States), Public
Developer of traditional pharmaceutical medicines
-
75/100
6th
Logo for Johnson & Johnson
Johnson & Johnson
1886, New Brunswick (United States), Public
Manufacturer and supplier of beauty care products, medical devices, and pharmaceutical products
-
75/100
7th
Logo for Roivant Sciences
Roivant Sciences
2014, New York City (United States), Public
Developer of therapeutics to treat neurology, oncology, rare, and endocrinology based diseases
$1.3B
71/100
8th
Logo for Novartis
Novartis
1996, Basel (Switzerland), Acquired
R&D focused on manufacturing of drugs for multiple therapeutic areas
-
71/100
9th
Logo for Roche
Roche
1896, Basel (Switzerland), Public
Developer of pharmaceuticals and diagnostics kits
-
70/100
10th
Logo for Genentech
Genentech
1976, San Francisco (United States), Acquired
R&D company focused on manufacturing drugs for multiple therapeutic areas
$72.5M
68/100
136th
Logo for Octozi
Octozi
2023, Russia, Seed
Accelerating life sciences with generative AI
$3M
40/100
lockGet insights and benchmarks for competitors of 2M+ companies! Sign up today!
Looking for more details on Octozi's competitors? Click here to see the top ones

Octozi's Investments and acquisitions

Octozi has made no investments or acquisitions yet.

Reports related to Octozi

Here is the latest report on Octozi's sector:

News related to Octozi

Media has covered Octozi for a total of 2 events in the last 1 year.
lockGet curated news about company updates, funding rounds, M&A deals and others. Sign up today!

FAQs about Octozi

Explore our recently published companies
Tracxn powers 1,000+ customers across 30+ countries
Accel PartnersPartechIN-Q-TEL - USFujitsuTenityStanford